Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.

Hdl Handle:
http://hdl.handle.net/10144/255348
Title:
Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.
Authors:
Wandeler, Gilles; Keiser, Olivia; Mulenga, Lloyd; Hoffmann, Christopher J; Wood, Robin; Chaweza, Thom; Brennan, Alana; Prozesky, Hans; Garone, Daniela; Giddy, Janet; Chimbetete, Cleophas; Boulle, Andrew; Egger, Matthias
Journal:
Journal of acquired immune deficiency syndromes (1999)
Abstract:
Tenofovir (TDF) is increasingly used in second-line antiretroviral treatment (ART) in sub-Saharan Africa. We compared outcomes of second-line ART containing and not containing TDF in cohort studies from Zambia and the Republic of South Africa (RSA).
Affiliation:
Division of International and Environmental Health, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland. gwandeler@ispm.unibe.ch
Issue Date:
1-Sep-2012
URI:
http://hdl.handle.net/10144/255348
DOI:
10.1097/QAI.0b013e3182632540
PubMed ID:
22743595
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/22743595
Type:
Article
Language:
en
Description:
Article approval pending
ISSN:
1944-7884
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorWandeler, Gillesen_GB
dc.contributor.authorKeiser, Oliviaen_GB
dc.contributor.authorMulenga, Lloyden_GB
dc.contributor.authorHoffmann, Christopher Jen_GB
dc.contributor.authorWood, Robinen_GB
dc.contributor.authorChaweza, Thomen_GB
dc.contributor.authorBrennan, Alanaen_GB
dc.contributor.authorProzesky, Hansen_GB
dc.contributor.authorGarone, Danielaen_GB
dc.contributor.authorGiddy, Janeten_GB
dc.contributor.authorChimbetete, Cleophasen_GB
dc.contributor.authorBoulle, Andrewen_GB
dc.contributor.authorEgger, Matthiasen_GB
dc.date.accessioned2012-12-11T20:40:46Z-
dc.date.available2012-12-11T20:40:46Z-
dc.date.issued2012-09-01-
dc.identifier.citationTenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies. 2012, 61 (1):41-8 J. Acquir. Immune Defic. Syndr.en_GB
dc.identifier.issn1944-7884-
dc.identifier.pmid22743595-
dc.identifier.doi10.1097/QAI.0b013e3182632540-
dc.identifier.urihttp://hdl.handle.net/10144/255348-
dc.descriptionArticle approval pending-
dc.description.abstractTenofovir (TDF) is increasingly used in second-line antiretroviral treatment (ART) in sub-Saharan Africa. We compared outcomes of second-line ART containing and not containing TDF in cohort studies from Zambia and the Republic of South Africa (RSA).en_GB
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/22743595en_GB
dc.rightsArchived with thanks to Journal of Acquired Immune Deficiency Syndromes (1999)en_GB
dc.subjectHIV/AIDSen_GB
dc.subject.meshAdenineen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAfrica South of the Saharaen_GB
dc.subject.meshAnti-Retroviral Agentsen_GB
dc.subject.meshAntiretroviral Therapy, Highly Activeen_GB
dc.subject.meshCD4 Lymphocyte Counten_GB
dc.subject.meshCohort Studiesen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHIV Infectionsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshPhosphonic Acidsen_GB
dc.subject.meshSouth Africaen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.subject.meshViral Loaden_GB
dc.subject.meshZambiaen_GB
dc.titleTenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.en
dc.typeArticleen
dc.contributor.departmentDivision of International and Environmental Health, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland. gwandeler@ispm.unibe.chen_GB
dc.identifier.journalJournal of acquired immune deficiency syndromes (1999)en_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.